Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$0.45 - $0.78 $18 - $31
40 New
40 $0
Q1 2022

May 16, 2022

SELL
$1.03 - $1.77 $31 - $54
-31 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$1.38 - $2.17 $42 - $67
31 New
31 $0

Others Institutions Holding IKT

About Inhibikase Therapeutics, Inc.


  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $33.8M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.